Mutations in ALK signaling pathways conferring resistance to ALK inhibitor treatment lead to collateral vulnerabilities in neuroblastoma cells.

Berlak M, Tucker E, Dorel M, Winkler A, McGearey A, Rodriguez-Fos E, da Costa BM, Barker K, Fyle E, Calton E, Eising S, Ober K, Hughes D, Koutroumanidou E, Carter P, Stankunaite R, Proszek P, Jain N, Rosswog C, Dorado-Garcia H, Molenaar JJ, Hubank M, Barone G, Anderson J, Lang P, Deubzer HE, Kunkele A, Fischer M, Eggert A, Kloft C, Henssen AG, Boettcher M, Hertwig F, Bluthgen N, Chesler L, Schulte JH
Mol Cancer. 2022 Jun 10;21(1):126. doi: 10.1186/s12943-022-01583-z. PubMed Article

Plasmids from Article

No plasmids are currently publicly available from Addgene for this article.